Cooper Companies shares climbed sharply in morning trading, rising roughly 8.1% after the medical device manufacturer posted fiscal second-quarter results that exceeded Wall Street forecasts on both the top and bottom lines and offered an encouraging update on the planned strategic review of its CooperSurgical unit.
The company reported non-GAAP earnings per share of $1.21, which topped the analyst consensus of $1.10 by 10%. Revenue for the quarter came in at $1.08 billion versus a $1.05 billion consensus. Those figures marked the tenth consecutive quarter in which the company exceeded earnings expectations. On a year-over-year basis, total revenue increased 8%, or 5% on an organic basis, setting a quarterly revenue record. Non-GAAP EPS advanced 26% to $1.21 for the period.
Executives used the earnings call to outline progress on the strategic review of CooperSurgical, which emerged as a key catalyst for investors. CEO Albert White said the business has drawn "robust interest" and added that, together with the board and advisers, management is "focused on identifying the optimal path forward to maximize shareholder value." That comment reinforced the idea that a meaningful strategic outcome could be forthcoming.
Management also flagged a more assertive approach to capital returns. CFO Brian Andrews said the company expects to be "much more aggressive" on buybacks going forward, and White indicated that a significant portion of proceeds from any CooperSurgical transaction would likely be funneled into repurchases. The combination of a clearer path for the division and a stronger buyback posture contributed materially to investor enthusiasm.
Analyst activity accompanied the operational update. Mizuho set a $85 price target on June 4, while Wells Fargo maintained an Equal Weight rating and assigned a $66 target. In addition, insider buying reinforced management confidence: CEO Albert White purchased 10,000 shares in recent insider activity for an estimated $808,000.
Today’s company-specific momentum occurred despite a broadly unfavorable macroeconomic backdrop. Labor data showed nonfarm payrolls rose by 172,000 jobs in May, well above the 85,000 estimate, and money markets increased the odds of a Federal Reserve rate hike before year-end to about 98%, up from roughly 60% prior to the jobs release. The stronger macro readings pressured major averages, with the S&P 500 down about 1.0% for the session, the Dow Jones Industrial Average slipping 0.2%, and the Nasdaq falling 1.8%.
Cooper’s gain stood in contrast to those market moves, driven largely by the company’s internal developments rather than broader sentiment. The stock had been under pressure over the previous year and was trading near a 52-week low of $58.89 before the report. The surprise beat on earnings, record quarterly revenue, a credible strategic review process for CooperSurgical, and a renewed commitment to capital returns combined to fuel the rally, lifting the share price to roughly $67.03 intraday.
Investors reacted to the mix of clean operational results and tangible steps that could accelerate shareholder returns. While management did not announce a definitive transaction for CooperSurgical, the disclosed interest and the board-led review process provided a credible framework for potential value-enhancing options. At the same time, the promise of increased buybacks, possibly financed in part by proceeds from any divestiture, offered a near-term mechanism to return capital to shareholders.
Bottom line: Cooper Companies delivered stronger-than-expected fiscal Q2 results and management commentary that together created a compelling set of company-specific catalysts. Those factors helped drive a double-digit relative move against a weakening market backdrop and shifted sentiment after a period of depressed share performance.